Trastuzumab HER2 inhibitors

Herceptin

Advanced breast cancer (metastatic)

All type of patients:  7 trials  - Blackwell - Gasparini - Huober - TAnDEM (Kaufman) - Marty - Slamon - von Minckwitz

trastuzumab + anastrozole vs anastrozole alone

No demonstrated result

trastuzumab + capecitabine vs capecitabine alone

No demonstrated result

trastuzumab + docetaxel vs docetaxel alone

No demonstrated result

trastuzumab + lapatinib vs lapatinib alone

No demonstrated result

trastuzumab + letrozole vs letrozole alone

No demonstrated result

trastuzumab + paclitaxel vs paclitaxel alone

No demonstrated result

trastuzumab + standard chemotherapy vs standard chemotherapy alone

No demonstrated result

See more clinical conditions

HER2 positive patients:  7 trials  - Blackwell - Gasparini - Huober - TAnDEM (Kaufman) - Marty - Slamon - von Minckwitz

trastuzumab + anastrozole vs anastrozole alone

No demonstrated result

trastuzumab + capecitabine vs capecitabine alone

No demonstrated result

trastuzumab + docetaxel vs docetaxel alone

No demonstrated result

trastuzumab + lapatinib vs lapatinib alone

No demonstrated result

trastuzumab + letrozole vs letrozole alone

No demonstrated result

trastuzumab + paclitaxel vs paclitaxel alone

No demonstrated result

trastuzumab + standard chemotherapy vs standard chemotherapy alone

No demonstrated result

Early breast cancer

HER2 positive patients:  11 trials  - NSABP B31 - BCIRG006 - Buzdar - FinHer - HERA - N9831 - NOAH - PACS-04 - N9831 (1) - N9831 (2) - FinHer (1)

trastuzumab vs control

No demonstrated result